The impact of 10-valent Pneumococcal Conjugate Vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children.
Maria Deloria Knoll,
Thomas N Williams,
Orin S Levine,
Laura L. Hammitt,
J. Anthony G. Scott
Posted 18 Jul 2018
bioRxiv DOI: 10.1101/369686
Posted 18 Jul 2018
Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes but the burden of pneumococcal disease in developing countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the impact of PCV on pneumonia incidence. Methods: We linked prospective hospital surveillance for clinically-defined WHO severe or very-severe pneumonia at Kilifi County Hospital from 2002-2015 to population surveillance at Kilifi Health and Demographic Surveillance System, comprising 45,000 children aged <5 years. Chest radiographs were read according to a WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in January 2011. In Kilifi, there was a catch-up campaign for children aged <5 years. We estimated the impact of PCV10 on pneumonia incidence through interrupted time series analysis accounting for seasonal and temporal trends. Findings: The incidence of admission with clinically-defined pneumonia in 2002/3 was 21.7/1000/year in children aged 2-59 months. This declined progressively over 13 years. By the end of March 2011, 61.1% of children aged 2-11 months received >=2 doses and 62.3% of children aged 12-59 months received >=1 dose of PCV10. Adjusted incidence rate ratios for admissions with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition), associated with PCV10 introduction, were 0.52 (95% CI 0.32-0.86), 0.73 (95% CI 0.54-0.97) and 0.63, (95% CI 0.31-1.26), respectively. The annual incidence of clinically-defined pneumonia in December 2010 was 12.2/1000; this was reduced by 3.3/1000 with PCV10 introduction. Interpretation: Over 13 years, hospitalisations for clinically-defined pneumonia declined progressively at Kilifi County Hospital but fell abruptly by 27% in association with PCV10 introduction. The incidence of radiologically-confirmed pneumonia fell by 48%. The burden of childhood pneumonia in Kilifi, Kenya, has been reduced substantially by PCV10. Funding: Gavi, Wellcome Trust
- Downloaded 303 times
- Download rankings, all-time:
- Site-wide: 97,158
- In epidemiology: 4,086
- Year to date:
- Site-wide: 142,719
- Since beginning of last month:
- Site-wide: 119,178
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!